Our results, performed in both PDXs and an in vitro NSCLC cell line, have clearly shown, in parallel to a strong synergistic activity of RAD001 + volasertib, an increase of HIF1 and a drop of CA9 gene and CAIX protein expression. The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.